Bulletin
Investor Alert

New York Markets Close in:

Market Pulse Archives

Feb. 12, 2021, 8:02 a.m. EST

CureVac's stock is up 6% as it begins regulatory process for its COVID-19 vaccine in the E.U.

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    CureVac N.V. (CVAC)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of CureVac /zigman2/quotes/219999729/composite CVAC -2.36% gained 6.0% in premarket trading on Friday after the company said it started a rolling submission for its experimental mRNA-based COVID-19 vaccine in the European Union. The vaccine is currently being tested in a Phase 3 clinical trial in Europe and Latin America. CureVac's stock has soared 64.4% over the past three months, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.93% is up 9.6%.

/zigman2/quotes/219999729/composite
US : U.S.: Nasdaq
$ 42.59
-1.03 -2.36%
Volume: 283,399
Dec. 2, 2021 11:45a
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$8.15 billion
Rev. per Employee
$100,563
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,555.06
+42.02 +0.93%
Volume: 1.07B
Dec. 2, 2021 11:46a
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.